Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate
Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate
Urinary tract infections are among the most prevalent microbial diseases and their financial
 burden on society is substantial. The use of bacteriophages against bacterial pathogens has
 gained over the last years a renewed interest, because of the continuing increase in
 antibiotic resistance worldwide. Thus, the aim of this study is to investigate the efficacy
 of intravesical bacteriophage treatment to normalize urine culture compared to intravesical
 placebo or standard antibiotic treatment in a randomized controlled trial following a pilot
 phase.
Inclusion Criteria:

 -  Patients with urinary tract infections who are scheduled for transurethral resection
 of the prostate with urine culture (taken by mid-stream urine; or from the existing
 transurethral or suprapubic catheter) ≥104 colony forming units /mL of predefined
 uropathogens, including Enterococcus spp., Escherichia coli, Proteus mirabilis,
 Pseudomonas aeruginosa, Staphylococcus spp., and Streptococcus spp. and lower urinary
 tract symptoms such as urgency, frequency, dysuria, increased number of incontinence
 episodes

 -  Written informed consent.

 Exclusion Criteria:

 -  Fever >38°C

 -  CRP >100mg/L

 -  Acute prostatitis

 -  Concomitant fungal urinary tract infection

 -  Current antibiotic treatment or antibiotic treatment within the last 7 days
 (exceptions: subjects with an active catheter associated urinary tract infection who
 have received prior antibiotics may be enrolled provided a minimum of 48 hours has
 elapsed between the last dose of the prior antibiotic and the time of obtaining the
 baseline urine specimen. Subjects receiving current antibiotic prophylaxis for
 catheter associated urinary tract infection who present signs and symptoms consistent
 with an active new catheter associated infection may be enrolled provided all other
 eligibility criteria are met including obtaining a pre-treatment qualifying baseline
 urine culture)

 -  Any rapidly progressing disease or immediately life-threatening illness including but
 not limited to: acute hepatic failure, respiratory failure, and septic shock

 -  No informed consent